- Stocks
- Healthcare
- NYSE: MRK

Price (delayed)

$110.85

Market cap

$281.05B

P/E Ratio

18.38

Dividend/share

$2.76

EPS

$6.03

Enterprise value

$300.32B

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the

The gross profit has grown by 33% year-on-year and by 3.3% since the previous quarter

The revenue has grown by 28% YoY and by 3.2% from the previous quarter

The net income has surged by 112% year-on-year but it has declined by 8% since the previous quarter

The EPS has soared by 112% YoY but it has contracted by 8% from the previous quarter

What are the main financial stats of MRK

Market
Valuations
Earnings

Shares outstanding

2.54B

Market cap

$281.05B

Enterprise value

$300.32B

Price to earnings (P/E)

18.38

Price to book (P/B)

6.32

Price to sales (P/S)

4.76

EV/EBIT

17.91

EV/EBITDA

14.57

EV/Sales

5.09

Revenue

$58.97B

EBIT

$16.77B

EBITDA

$20.62B

Free cash flow

$15.25B

Per share
Balance sheet
Liquidity

EPS

$6.03

Free cash flow per share

$6.02

Book value per share

$17.55

Revenue per share

$23.28

TBVPS

$25.48

Total assets

$107.08B

Total liabilities

$62.56B

Debt

$30.42B

Equity

$44.46B

Working capital

$10.56B

Debt to equity

0.68

Current ratio

1.46

Quick ratio

0.9

Net debt/EBITDA

0.93

Margins
Efficiency
Dividend

EBITDA margin

35%

Gross margin

70.5%

Net margin

25.9%

Operating margin

30.7%

Return on assets

14.3%

Return on equity

36.6%

Return on invested capital

26.9%

Return on capital employed

19.9%

Return on sales

28.4%

Dividend yield

2.49%

DPS

$2.76

Payout ratio

45.8%

How has the Merck stock price performed over time

Intraday

0.69%

1 week

0.96%

1 month

9.21%

1 year

51.41%

YTD

44.64%

QTD

28.72%

How have Merck's revenue and profit performed over time

Revenue

$58.97B

Gross profit

$41.57B

Operating income

$18.08B

Net income

$15.26B

Gross margin

70.5%

Net margin

25.9%

Merck's operating income has soared by 193% YoY but it has decreased by 4.3% from the previous quarter

Merck's operating margin has surged by 129% YoY but it has decreased by 7% QoQ

The net income has surged by 112% year-on-year but it has declined by 8% since the previous quarter

MRK's net margin has surged by 66% year-on-year but it is down by 11% since the previous quarter

What is Merck's growth rate over time

What is Merck stock price valuation

P/E

18.38

P/B

6.32

P/S

4.76

EV/EBIT

17.91

EV/EBITDA

14.57

EV/Sales

5.09

The EPS has soared by 112% YoY but it has contracted by 8% from the previous quarter

The P/E is 47% lower than the 5-year quarterly average of 34.7 but 27% higher than the last 4 quarters average of 14.4

Merck's equity has increased by 24% YoY and by 2.8% from the previous quarter

The price to book (P/B) is 23% higher than the last 4 quarters average of 5.1 but 2% lower than the 5-year quarterly average of 6.4

The revenue has grown by 28% YoY and by 3.2% from the previous quarter

MRK's P/S is 21% above its last 4 quarters average of 3.9 and 5% above its 5-year quarterly average of 4.5

How efficient is Merck business performance

The company's return on assets has surged by 81% YoY but it fell by 11% QoQ

The ROIC has soared by 68% YoY but it fell by 12% QoQ

Merck's ROE has soared by 54% YoY but it has decreased by 13% from the previous quarter

The ROS has soared by 50% YoY but it has contracted by 12% from the previous quarter

What is MRK's dividend history

DPS

$2.76

Dividend yield

2.49%

Payout ratio

45.8%

Recent dividends

How did Merck financials performed over time

The total assets is 71% more than the total liabilities

MRK's quick ratio is up by 15% year-on-year and by 6% since the previous quarter

The total assets has grown by 15% YoY

MRK's debt is 32% smaller than its equity

Merck's equity has increased by 24% YoY and by 2.8% from the previous quarter

MRK's debt is up by 15% year-on-year but it is down by 3.9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.